Trium Capital’s Esperion Therapeutics ESPR Stock Holding History

Trium Capital’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$35.3M	Buy	+11,158,150	New	+$31.2M	21.69%	2

Other funds holding ESPR

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Eleva Capital Paris, France $343M AUM

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

CFS Investment Advisory Services Totowa, New Jersey $1.5B AUM 20.41% 1-Year Est. Return

Spire Wealth Management Mclean, Virginia $3.31B AUM 38.78% 1-Year Est. Return

Wealth Enhancement Advisory Services

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Affinity Capital Advisors Berkeley, California $810M AUM 24.85% 1-Year Est. Return

MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return

City State Bank Norwalk, Iowa $436M AUM 32.32% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Trium Capital's ESPR Position: Q2 2026 in Review

Trium Capital opened a new position in Esperion Therapeutics (ESPR) in Q2 2026: 11,158,150 shares worth $35.3M. The stake represents 21.69% of the portfolio and ranks #2 among its holdings.

11 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

Trium Capital held 11,158,150 shares of Esperion Therapeutics worth $35.3M as of Q2 2026.
Esperion Therapeutics was a new Trium Capital position in Q2 2026.
Esperion Therapeutics made up 21.69% of Trium Capital's portfolio in Q2 2026, its #2 holding.
11 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Trium Capital's 13F filing for Q2 2026, filed 16 Jul 2026.